Genetic polymorphisms of arylamine N-acetyltransferases 1 and 2 and the likelihood of developing pediatric acute lymphoblastic leukemia
Article
-
- Overview
-
- Research
-
- Identity
-
- Additional Document Info
-
- View All
-
Overview
abstract
-
Acute lymphoblastic leukemia (ALL) is one of the main causes of death in children and is associated with both genetic susceptibility and environmental factors. Genes encoding the arylamine N-acetyltransferases 1 and 2 (NAT1 and NAT2) isoenzymes are highly polymorphic among populations. Single-nucleotide polymorphism analysis was performed by real-time polymerase chain reaction from the genomic DNA of 225 healthy subjects and 57 children with ALL diagnoses. Significant associations were found between the development of ALL and the presence of the haplotypes NAT1*3 (Odds ratio [OR], 2.1), NAT1*4 (OR, 1.92), NAT2*6B (OR, 3.30), NAT2*6J (OR, 3.25) and NAT2*7A (OR, 2.45) and the NAT1 rapid (OR, 6.69) and NAT2 slow phenotypes (OR, 2.95). Our results indicate that haplotypes that provide rapid NAT1 and slow NAT2 acetylating phenotypes may influence the development of ALL in children. © 2017, © 2017 Informa UK Limited, trading as Taylor %26 Francis Group.
-
Acute lymphoblastic leukemia (ALL) is one of the main causes of death in children and is associated with both genetic susceptibility and environmental factors. Genes encoding the arylamine N-acetyltransferases 1 and 2 (NAT1 and NAT2) isoenzymes are highly polymorphic among populations. Single-nucleotide polymorphism analysis was performed by real-time polymerase chain reaction from the genomic DNA of 225 healthy subjects and 57 children with ALL diagnoses. Significant associations were found between the development of ALL and the presence of the haplotypes NAT1*3 (Odds ratio [OR], 2.1), NAT1*4 (OR, 1.92), NAT2*6B (OR, 3.30), NAT2*6J (OR, 3.25) and NAT2*7A (OR, 2.45) and the NAT1 rapid (OR, 6.69) and NAT2 slow phenotypes (OR, 2.95). Our results indicate that haplotypes that provide rapid NAT1 and slow NAT2 acetylating phenotypes may influence the development of ALL in children. © 2017, © 2017 Informa UK Limited, trading as Taylor & Francis Group.
publication date
funding provided via
published in
Research
keywords
-
acute lymphoblastic leukemia; Arylamine N-acetyltransferases; NAT1 and NAT2; SNP arylamine acetyltransferase; arylamine n acetyltransferase 1; arylamine n acetyltransferase 2; genomic DNA; unclassified drug; arylamine acetyltransferase; isoenzyme; N-acetyltransferase 1; NAT2 protein, human; acute lymphoblastic leukemia; adolescent; adult; allele; Article; child; controlled study; environmental factor; gene; genetic analysis; genetic susceptibility; haplotype; human; major clinical study; phenotype; priority journal; real time polymerase chain reaction; single nucleotide polymorphism; acute lymphoblastic leukemia; aged; gene frequency; genetic predisposition; genetics; genotype; infant; middle aged; preschool child; young adult; Adolescent; Adult; Aged; Arylamine N-Acetyltransferase; Child; Child, Preschool; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Infant; Isoenzymes; Middle Aged; Polymorphism, Single Nucleotide; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Young Adult
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional Document Info
start page
end page
volume
issue